Lawrence Garbo

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Hedy L. Kindler, Donald Richards, Lawrence Garbo et al. · Annals of Oncology · 2012 · 191 citations · Full text

Medicine, Oncology, Pharmacology +14

Thalidomide and rituximab in Waldenstrom macroglobulinemia

Steven P. Treon, Jacob D. Soumerai, Andrew R. Branagan et al. · Blood · 2008 · 143 citations · Full text

Medicine, Hematology, Pharmacotherapy +6

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

David S. Ettinger, Robert M. Jotte, Paul Lorigan et al. · Journal of Clinical Oncology · 2010 · 124 citations

Medicine, Oncology, Pharmacology +14

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Marwan Fakih, Kanwal Raghav, David Chang et al. · Journal of Clinical Oncology · 2021 · 74 citations

Pharmacy, Oncology, Pharmacotherapy +12